Postmenopausal Osteoporosis & Bone Mineral Density (BMD)

Significant improvement in BMD at each dose studied (0.625 mg, 0.45 mg, and 0.3 mg) at 24 months1,2
When prescribing solely for the prevention of postmenopausal osteoporosis, hormone therapy should be considered only for women at significant risk of osteoporosis, and non-estrogen medications should be carefully considered.
BMD Chart
All endpoints are statistically significant vs placebo.
*Final evaluation was cycle 26 for those who completed the study and the last available evaluation for those who discontinued early. Each cycle was 28 days.
Anteroposterior lumbar spine.
STUDY DESCRIPTION:
Lindsay, et al: HOPE trial substudy. Data from the Health, Osteoporosis, Progestin, Estrogen (HOPE) study: a 2-year trial of 2673 healthy, postmenopausal women (average age 53.3 years +/- 4.9 years) with a uterus. This study reflects the results from the second half of the study, which examined the effects of 3 dosage combinations of conjugated equine estrogen (CEE) therapy (including 2 lower dosages) with and without medroxyprogesterone acetate (MPA) on bone density and biochemical markers of bone turnover in 695 postmenopausal women. In addition to estrogen, all patients received 600 mg of calcium carbonate daily.
REFERENCES:
  1. Premarin [prescribing information]. New York, NY: Pfizer Inc.; September 2018. 
  2. Lindsay R, Gallagher J, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287(20):2668-2676.
  3. Data on file. Pfizer Inc., New York, NY.